LBB-66

Pharmaceutical compound From Wikipedia, the free encyclopedia

LBB-66, also known as lysergic acid dibutylamide or as N,N-dibutyllysergamide, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD; LSD-25).[1][2][3] It is the derivative of LSD in which the N,N-diethyl groups have been replaced with N,N-dibutyl groups.[1][2][3]

Other namesLBB66; LA-dibutylamide; Lysergic acid dibutylamide; N,N-Dibutyllysergamide; N,N-Dibutyl-6-methyl-9,10-didehydroergoline-8β-carboxamide
ATC code
  • None
Quick facts Clinical data, Other names ...
LBB-66
Clinical data
Other namesLBB66; LA-dibutylamide; Lysergic acid dibutylamide; N,N-Dibutyllysergamide; N,N-Dibutyl-6-methyl-9,10-didehydroergoline-8β-carboxamide
Drug classSerotonin receptor modulator
ATC code
  • None
Identifiers
  • (6aR,9R)-N,N-dibutyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
PubChem CID
ChemSpider
Chemical and physical data
FormulaC24H33N3O
Molar mass379.548 g·mol−1
3D model (JSmol)
  • CCCCN(CCCC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
  • InChI=1S/C24H33N3O/c1-4-6-11-27(12-7-5-2)24(28)18-13-20-19-9-8-10-21-23(19)17(15-25-21)14-22(20)26(3)16-18/h8-10,13,15,18,22,25H,4-7,11-12,14,16H2,1-3H3/t18-,22-/m1/s1
  • Key:GVTRJLOTMIDJSS-XMSQKQJNSA-N
Close

The drug has about 31% or around one-third of the antiserotonergic activity of LSD in the isolated rat uterus in vitro.[1][4][5][6] In contrast to other assessed lysergamides, it has been said to bind practically irreversibly in this context.[5] Unlike LSD, LBB-66 is said to be devoid of psychedelic effects in humans, with a hallucinogenic potency relative to LSD of 0% stated, but the tested doses not given.[1]

LBB-66 was first described in the scientific literature by Albert Hofmann and colleagues by 1955.[7][8][9][10]

See also

References

Related Articles

Wikiwand AI